MHRA-101572-PIP01-24

Key Facts

Active Substance
  • Nogapendekin alfa
  • Inbakicept
Invented Name
  • ANKTIVA
  • ANKTIVA
PIP Number MHRA-101572-PIP01-24
Pharmaceutical form(s)
Pharmaceutical form(s):
  • All pharmaceutical forms
Therapeutic area
  • Uro-Nephrology
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of malignant bladder neoplasms
Route(s) of administration
Route(s) of administration:
  • All routes of administration
PIP applicant
  • Serum Life Science Europe GmbH
  • Country Germany
  • Tel +495111699080
  • Email info@sls-eu.com
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Nogapendekin alfaInbakicept.pdf
Published Date 29/11/2024